• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低分子量壳聚糖在肾脏中的蓄积增强:壳聚糖 N-乙酰化对肾脏靶向性影响的研究。

Enhanced accumulation of low-molecular-weight chitosan in kidneys: a study on the influence of N-acetylation of chitosan on the renal targeting.

机构信息

Key Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, PR China.

出版信息

J Drug Target. 2011 Aug;19(7):540-51. doi: 10.3109/1061186X.2010.521158.

DOI:10.3109/1061186X.2010.521158
PMID:21767121
Abstract

PURPOSE

To investigate the influence of N-acetylation of chitosan on the renal targeting.

METHODS

Hydroxyethyl chitosans (HECs) with different N-acetylation degrees of 10.0%, 52.7%, and 81.8% (HECs-10, HECs-53, and HECs-82) were synthesized. Then, in vitro evaluations including cellular uptake and cytotoxicity were performed. Finally, tissue distribution of HECs in normal mice and megalin-shedding mice models were evaluated.

RESULTS

HECs-10 exhibited the highest binding affinity and uptake capacity to MDCK cells, expressing the megalin receptor. Additionally, cytotoxicity assay showed that there were no obvious effects of HECs on the viability of L929 and MDCK cells. Consistent with the cellular uptake study, it was shown in vivo study that all HECs exhibited renal-targeting profile. Especially, HECs-10 with low N-acetylation overwhelmingly accumulated in the kidneys, while urinary excretion of HECs-10 was low, in comparison with that of HECs-53 and HECs-82. Finally, the renal accumulation of HECs in megalin-shedding mice was dramatically reduced by over ~50% as compared with that in normal animals and the specific renal uptake of HECs was increasingly inhibited with the N-acetylation increased.

CONCLUSION

Inspired by these observations, we can conclude that decreasing the N-acetylation could enhance accumulation of low-molecular-weight chitosan in kidneys and amino groups in the structure could be essential for renal-targeting profile of chitosan.

摘要

目的

研究壳聚糖的 N-乙酰化对其肾靶向性的影响。

方法

合成了不同 N-乙酰化度(10.0%、52.7%和 81.8%)的羟乙基壳聚糖(HECs),即 HECs-10、HECs-53 和 HECs-82。然后,进行了包括细胞摄取和细胞毒性在内的体外评价。最后,在正常小鼠和 megalin 脱落小鼠模型中评价了 HECs 在组织中的分布。

结果

HECs-10 对表达 megalin 受体的 MDCK 细胞表现出最高的结合亲和力和摄取能力。此外,细胞毒性试验表明 HECs 对 L929 和 MDCK 细胞的活力没有明显影响。与细胞摄取研究一致,体内研究表明所有 HECs 均表现出肾靶向特征。特别是,低 N-乙酰化的 HECs-10 大量积聚在肾脏中,而 HECs-10 的尿排泄量较低,与 HECs-53 和 HECs-82 相比。最后,与正常动物相比,megalin 脱落小鼠中 HECs 的肾积累减少了约 50%以上,并且随着 N-乙酰化的增加,HECs 的特异性肾摄取受到越来越大的抑制。

结论

受这些观察结果的启发,我们可以得出结论,降低 N-乙酰化度可以增强低分子量壳聚糖在肾脏中的积累,并且结构中的氨基对于壳聚糖的肾靶向特征是必不可少的。

相似文献

1
Enhanced accumulation of low-molecular-weight chitosan in kidneys: a study on the influence of N-acetylation of chitosan on the renal targeting.低分子量壳聚糖在肾脏中的蓄积增强:壳聚糖 N-乙酰化对肾脏靶向性影响的研究。
J Drug Target. 2011 Aug;19(7):540-51. doi: 10.3109/1061186X.2010.521158.
2
Specific renal uptake of randomly 50% N-acetylated low molecular weight chitosan.随机50% N-乙酰化低分子量壳聚糖的特异性肾脏摄取。
Mol Pharm. 2009 Jan-Feb;6(1):305-14. doi: 10.1021/mp800078a.
3
Determination of the pattern of acetylation of low-molecular-weight chitosan used in biomedical applications.用于生物医学应用的低分子量壳聚糖乙酰化模式的测定。
J Pharm Biomed Anal. 2009 Nov 1;50(4):587-90. doi: 10.1016/j.jpba.2008.09.048. Epub 2008 Oct 8.
4
Kidney-specific drug delivery system for renal fibrosis based on coordination-driven assembly of catechol-derived chitosan.基于儿茶酚衍生壳聚糖的配位驱动组装的用于肾纤维化的肾脏特异性药物传递系统。
Biomaterials. 2014 Aug;35(25):7157-71. doi: 10.1016/j.biomaterials.2014.04.106. Epub 2014 May 23.
5
Influence of the degree of acetylation on the enzymatic degradation and in vitro biological properties of trimethylated chitosans.乙酰化程度对三甲基化壳聚糖酶促降解及体外生物学性质的影响。
Biomaterials. 2009 Jun;30(18):3129-35. doi: 10.1016/j.biomaterials.2009.03.013. Epub 2009 Mar 31.
6
In vitro and in vivo degradation behavior of acetylated chitosan porous beads.乙酰化壳聚糖多孔微球的体外和体内降解行为
J Biomater Sci Polym Ed. 2008;19(4):453-66. doi: 10.1163/156856208783719482.
7
Randomly 50% N-acetylated low molecular weight chitosan as a novel renal targeting carrier.随机选取50%的N-乙酰化低分子量壳聚糖作为一种新型的肾脏靶向载体。
J Drug Target. 2007 May;15(4):269-78. doi: 10.1080/10611860701289875.
8
In-vivo tumor targeting of pluronic-based nano-carriers.基于普朗尼克的纳米载体在体内的肿瘤靶向作用。
J Control Release. 2010 Oct 1;147(1):109-17. doi: 10.1016/j.jconrel.2010.06.010. Epub 2010 Jun 19.
9
Effect of polymer molecular weight on the tumor targeting characteristics of self-assembled glycol chitosan nanoparticles.聚合物分子量对自组装壳聚糖纳米粒肿瘤靶向特性的影响。
J Control Release. 2007 Oct 8;122(3):305-14. doi: 10.1016/j.jconrel.2007.04.009. Epub 2007 Apr 19.
10
[Study on N-acetylated chitosans by FTIR and XRD].[利用傅里叶变换红外光谱和X射线衍射对N-乙酰化壳聚糖的研究]
Guang Pu Xue Yu Guang Pu Fen Xi. 2006 Jul;26(7):1217-20.

引用本文的文献

1
Nanomedicines for the management of diabetic nephropathy: present progress and prospects.纳米医学在糖尿病肾病管理中的应用:现状与展望。
Front Endocrinol (Lausanne). 2023 Nov 3;14:1236686. doi: 10.3389/fendo.2023.1236686. eCollection 2023.
2
Nano-Technological Approaches for Targeting Kidney Diseases With Focus on Diabetic Nephropathy: Recent Progress, and Future Perspectives.聚焦糖尿病肾病的靶向治疗肾脏疾病的纳米技术方法:最新进展与未来展望
Front Bioeng Biotechnol. 2022 May 13;10:870049. doi: 10.3389/fbioe.2022.870049. eCollection 2022.
3
Glycol chitosan-based tacrolimus-loaded nanomicelle therapy ameliorates lupus nephritis.
基于乙二醇壳聚糖的载他克莫司纳米胶束疗法可改善狼疮性肾炎。
J Nanobiotechnology. 2021 Apr 17;19(1):109. doi: 10.1186/s12951-021-00857-w.
4
Self-crosslinkable chitosan-hyaluronic acid dialdehyde nanoparticles for CD44-targeted siRNA delivery to treat bladder cancer.用于CD44靶向小干扰RNA递送以治疗膀胱癌的可自交联壳聚糖-透明质酸二醛纳米颗粒
Bioact Mater. 2020 Sep 8;6(2):433-446. doi: 10.1016/j.bioactmat.2020.08.019. eCollection 2021 Feb.
5
Nanomedicines for renal disease: current status and future applications.用于肾病的纳米药物:现状和未来应用。
Nat Rev Nephrol. 2016 Dec;12(12):738-753. doi: 10.1038/nrneph.2016.156. Epub 2016 Oct 31.
6
Kidney-targeted drug delivery systems.肾脏靶向给药系统。
Acta Pharm Sin B. 2014 Feb;4(1):37-42. doi: 10.1016/j.apsb.2013.12.005. Epub 2014 Jan 23.
7
Megalin-mediated specific uptake of chitosan/siRNA nanoparticles in mouse kidney proximal tubule epithelial cells enables AQP1 gene silencing.巨蛋白介导的壳聚糖/小干扰RNA纳米颗粒在小鼠肾近端小管上皮细胞中的特异性摄取可实现水通道蛋白1基因沉默。
Theranostics. 2014 Aug 13;4(10):1039-51. doi: 10.7150/thno.7866. eCollection 2014.
8
Low molecular weight hydroxyethyl chitosan-prednisolone conjugate for renal targeting therapy: synthesis, characterization and in vivo studies.低分子量羟乙基壳聚糖-泼尼松龙偶联物用于肾脏靶向治疗:合成、表征和体内研究。
Theranostics. 2012;2(11):1054-63. doi: 10.7150/thno.3705. Epub 2012 Nov 6.